DeepMed Research

MAYO CLINIC

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary

Established: 1889-01-01

Employees: 10K

Market Cap: -

Website: http://www.mayoclinic.org

Clinical Trials

Rituximab and Prednisone as First-Line Therapy in Treating Patients With Immune Thrombocytopenic Purpura

Early Phase 1

Completed

Conditions: Nonneoplastic Condition

Interventions: Biological: Rituximab
Drug: Prednisone

First Posted Date: 2007-06-14

Last Posted Date: 2014-10-17

Lead Sponsor: Mayo Clinic

Target Recruit Count: 22

Registration Number: NCT00486421

Locations: 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States

Samarium Sm 153 Lexidronam Pentasodium Combined With Zoledronic Acid or Pamidronate in Treating Patients With Relapsed or Refractory Multiple Myeloma and Bone Pain

Phase 1

Completed

Conditions: Multiple Myeloma and Plasma Cell Neoplasm
Pain

Interventions: Drug: Pamidronate
Drug: Zoledronic acid
Radiation: Sm 153 lexidronam

First Posted Date: 2007-06-05

Last Posted Date: 2018-08-14

Lead Sponsor: Mayo Clinic

Target Recruit Count: 39

Registration Number: NCT00482378

Locations: 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States

Bevacizumab in Treating Patients With Relapsed or Refractory Multiple Myeloma

Phase 2

Completed

Conditions: Multiple Myeloma and Plasma Cell Neoplasm

First Posted Date: 2007-06-05

Last Posted Date: 2011-05-11

Lead Sponsor: Mayo Clinic

Target Recruit Count: 42

Registration Number: NCT00482495

Locations: 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States

Melphalan, Prednisone, and Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma

Phase 1

Completed

Conditions: Multiple Myeloma and Plasma Cell Neoplasm

Interventions: Drug: lenalidomide
Drug: melphalan
Drug: prednisone

First Posted Date: 2007-05-24

Last Posted Date: 2019-10-11

Lead Sponsor: Mayo Clinic

Target Recruit Count: 33

Registration Number: NCT00477750

Locations: 🇺🇸
Mayo Clinic in Arizona, Scottsdale, Arizona, United States
🇺🇸
Mayo Clinic in Florida, Jacksonville, Florida, United States
🇺🇸
Mayo Clinic, Rochester, Minnesota, United States

Rituximab, Yttrium Y 90 Ibritumomab Tiuxetan, Melphalan, and Autologous Peripheral Stem Cell Transplant in Treating Patients With Previously Treated Multiple Myeloma

Phase 1

Completed

Conditions: Multiple Myeloma and Plasma Cell Neoplasm

Interventions: Biological: rituximab
Drug: melphalan
Biological: Stem Cell
Biological: Sargramostim (GM-CSF)
Radiation: 90Y-Zevalin
Biological: 111In Zevalin

First Posted Date: 2007-05-24

Last Posted Date: 2018-05-14

Lead Sponsor: Mayo Clinic

Target Recruit Count: 30

Registration Number: NCT00477815

Locations: 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States

Low-Dose Melphalan and Dexamethasone Compared With High-Dose Melphalan Followed By Autologous Stem Cell Transplant in Treating Patients With Primary Systemic Amyloidosis

Phase 3

Completed

Conditions: Multiple Myeloma and Plasma Cell Neoplasm

Interventions: Biological: filgrastim
Drug: dexamethasone
Drug: melphalan
Procedure: autologous hematopoietic stem cell transplantation

First Posted Date: 2007-05-24

Last Posted Date: 2016-05-17

Lead Sponsor: Mayo Clinic

Target Recruit Count: 89

Registration Number: NCT00477971

Locations: 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States

Lenalidomide, Cyclophosphamide, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma

Phase 2

Completed

Conditions: Multiple Myeloma and Plasma Cell Neoplasm

Interventions: Drug: cyclophosphamide
Drug: dexamethasone
Drug: lenalidomide

First Posted Date: 2007-05-24

Last Posted Date: 2011-08-31

Lead Sponsor: Mayo Clinic

Target Recruit Count: 53

Registration Number: NCT00478218

Locations: 🇺🇸
Mayo Clinic Cancer Center, Rochester, Minnesota, United States
🇺🇸
Mayo Clinic Scottsdale, Scottsdale, Arizona, United States

Samarium Sm 153 Lexidronam Pentasodium and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma

Phase 1

Completed

Conditions: Multiple Myeloma and Plasma Cell Neoplasm

First Posted Date: 2007-05-24

Last Posted Date: 2011-05-11

Lead Sponsor: Mayo Clinic

Target Recruit Count: 50

Registration Number: NCT00478075

Locations: 🇺🇸
Mayo Clinic Scottsdale, Scottsdale, Arizona, United States
🇺🇸
Mayo Clinic Cancer Center, Rochester, Minnesota, United States
🇺🇸
Mayo Clinic - Jacksonville, Jacksonville, Florida, United States

Sorafenib and Everolimus in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma

Phase 1

Completed

Conditions: Lymphoma
Multiple Myeloma and Plasma Cell Neoplasm

Interventions: Drug: RAD001
Drug: Sorafenib

First Posted Date: 2007-05-17

Last Posted Date: 2019-08-20

Lead Sponsor: Mayo Clinic

Target Recruit Count: 103

Registration Number: NCT00474929

Locations: 🇺🇸
Mayo Clinic Cancer Center, Rochester, Minnesota, United States
🇺🇸
Holden Comprehensive Cancer Center at University of Iowa, Iowa City, Iowa, United States

Vaccine Therapy and GM-CSF With or Without Low-Dose Aldesleukin in Treating Patients With Stage II, Stage III, or Stage IV Melanoma

Phase 1

Completed

Conditions: Melanoma (Skin)

Interventions: Biological: MART-1 antigen
Biological: IL-2
Biological: gp100 antigen
Biological: GM-CSF
Biological: MART-1a peptide

First Posted Date: 2007-05-07

Last Posted Date: 2019-02-19

Lead Sponsor: Mayo Clinic

Target Recruit Count: 20

Registration Number: NCT00470015

Locations: 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy